Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.

Lung cancer (Amsterdam, Netherlands) - 1 Jun 2008

Zampa Germano, Moscato Michele, Brannigan Brian W, Morabito Alessandro, Bell Daphne W, Normanno Nicola

Abstract excerpt

We describe two non-small-cell lung cancer (NSCLC) patients in which treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs) gefitinib produced a prolonged control of bone disease. In the first patient, a 48-year-old male with adenocarcinoma (ADC) of the lung a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Bone Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Drug Resistance, Neoplasm

Share to Gefitinib

Share to Neoplasm Recurrence, Local

Share to Quinazolines

Source

Identifiers

PMID: 18079016
DOI: 10.1016/j.lungcan.2007.11.002

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18079016-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.PMID 18079016Read ↗

Osteosclerotic Change as a Therapeutic Response to Gefitinib in Symptomatic Non-Small Cell Lung Cancer Bone MetastasisSemantic proximity Read ↗

Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis.Semantic proximity Read ↗

A case of lung adenocarcinoma with postoperative recurrence of multiple bone metastases that showed a gradual complete response to combined administration of erlotinib and zoledronic acid.Semantic proximity Read ↗

Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.Semantic proximity Read ↗

Tumor-free osteosclerotic lesions in patients treated for metastatic melanoma using BRAF inhibitors.Semantic proximity Read ↗

Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.Semantic proximity Read ↗

Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report.Semantic proximity Read ↗

Prolonged durability of extensive contiguous spinal metastasis stabilization in non-small cell lung cancer patients receiving targeted therapy: two case reports and a literature review.Semantic proximity Read ↗

Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors.Semantic proximity Read ↗

The effect of bevacizumab for bone scintigraphy imaging: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.